Smart Insulin Pens Market (2025-2032)
The Smart Insulin Pens Market is expected to reach $ 776.5 Million by 2032, at a CAGR of 11.2% from 2025 to 2032. Smart Insulin Pens Market Size & Forecast This market's growth is being driven by a spike in diabetes cases, a preference for digital health solutions, technological advancements in smart
- Published
- Aug 2024
- Pages
- 270
- Format
- PDF + Excel
- Report ID
- MRHC - 1041300
- Base year
- 2024
- 2032 · FORECAST
- $776.5M
- 2032
- $776.5M
- CAGR 2025–2032
- 11.2%
2024 baseline · 2025–2032 forecast at 11.2% CAGR · hover a bar for the value
Key highlights
By Product: In 2025, the Insulin Cartridges Segment to Dominate the Smart Insulin Pens Market
By Connectivity: In 2025, the Bluetooth Connectivity Segment to Dominate the Smart Insulin Pens Market
By Glucose Monitor Compatibility: the Blood Glucose Monitors (BGMs) Compatible Pens Segment to Dominate the Smart Insulin Pens Market
By Purchase Channel: the Retail Pharmacies to Dominate the Smart Insulin Pens Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 270 |
| Format | |
| Forecast Period | 2025–2032 |
| Base Year | 2024 |
| CAGR (Value) | 11.2% |
| Market Size (Value) | USD 776.5 Million by 2032 |
| Segments Covered | By Product · Reusable Insulin Pens · Disposable Prefilled Insulin Pens · Insulin Cartridges · Accessories · (Note: Accessories include data transmitters & injector ports.) · By Connectivity · Bluetooth Connectivity · Near Field Communication (NFC) Connectivity · By Glucose Monitor Compatibility · Blood Glucose Monitor (BGM) Compatible Pens · Continuous Glucose Monitor (CGM) Compatible Pens · By Purchase Channel · Hospital Pharmacies · Retail Pharmacies · Online/E-commerce Platforms |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Austria, Netherlands, Rest of Europe) Asia–Pacific (Japan, China, India, South Korea, Australia, Rest of Asia–Pacific), Latin America, and Middle East & Africa |
| Key Companies | Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Medtronic plc (Ireland), Emperra GmbH E-Health Technologies (Germany), pendiq GmbH (Germany), Jiangsu Delfu medical device Co., Ltd (China), Tandem Diabetes Care, Inc. (U.S.), Ypsomed AG (Switzerland), and Bigfoot Biomedical, Inc. (U.S.), |
Report overview
Segments covered: product. Regions: North America, Europe.
This market's growth is being driven by a spike in diabetes cases, a preference for digital health solutions, technological advancements in smart insulin pens, an increase in demand for drug self-administration, and diabetes awareness initiatives. The expensive cost of smart insulin pens, along with the availability of alternatives, may limit market expansion.
Furthermore, rising demand for remote monitoring and telemedicine, partnerships and collaborations among smart insulin pen manufacturers, expanding economies, and personalized diabetes management are expected to create market growth. However, a lack of understanding about the use of smart insulin pens in developing nations, as well as a preference for traditional insulin delivery techniques, pose substantial challenges to the market's growth.
Moreover, the integration with Continuous Glucose Monitoring (CGM) systems is a prominent trend in the smart insulin pens market.
Report infographic
Market dynamics
5 factors across 3 forcesIncreasing Prevalence of Diabetes
Diabetes, a chronic condition caused by lack of physical activity, being overweight, heredity, and lack of insulin in the body, is a significant driver of the smart insulin pens market. The increasing prevalence of diabetes, as reported by the International Diabetes Federation (IDF) and the Centers for Disease Control and Prevention (CDC), is expected to significantly impact the market.
In addition, in 2021, 61 million people lived with Type 2 Diabetes (T2D) in Europe. (Source: International Diabetes Federation (IDF)). Diabetes requires regular management and monitoring of insulin levels. Smart insulin pens automatically record when a person injects insulin, identifying the amount injected and the time of day. Thus, the rising prevalence of diabetes is driving the growth of the smart insulin pens market.
Technological Advancements in Smart Insulin Pens
Technological advances in insulin delivery were restricted to insulin pump users, and traditional methods of insulin delivery, such as vials, syringes, and insulin pens, were unaffected by modern digital technologies. With the recent introduction of smart insulin pens, an increasingly wider population with diabetes is able to utilize a digital tool to simplify and improve insulin therapy.
Smart insulin pens offer several advantages over traditional insulin delivery systems, such as preventing skipping or missing scheduled doses, calculating each dose by utilizing the patient's current carbohydrate intake, blood glucose level, meal size, active insulin, and the parameters indicated by medical professionals, delivering diabetes data analysis to the doctor as required, and connecting with a smartphone and watch with established diabetes.
In addition, enhanced data tracking caps were approved and added to disposable insulin pens to track doses. For instance, in May 2021, Bigfoot Biomedical Inc. (U.S.) obtained FDA 510(k) clearance approval for the Bigfoot Unity diabetes management system, which includes linked smartpen caps for insulin pens used to treat type 1 and 2 diabetes. Such advances present an opportunity for the smart insulin pens market.
Table of contents
12 chapters · 98 sections · 270 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Product | Insulin Cartridges | — |
| By Connectivity | Bluetooth Connectivity | — |
| By Glucose Monitor Compatibility | Blood Glucose Monitors (BGMs) Compatible Pens | — |
| By Purchase Channel | Retail Pharmacies | — |
By Product
- The insulin cartridges segment is expected to account for the largest share of 63.3% of the smart insulin pens market.
- This segment’s large market share is attributed to the increasing number of diabetes cases and benefits offered by insulin cartridges, such as providing greater comfort and ease of use than standard vials and syringes.
- Pre-filled cartridges are readily put into insulin pens, making insulin administration easier for people with diabetes.
- Moreover, this segment is also expected to register the highest CAGR of 12.5% during the forecast period.
By Connectivity
- The Bluetooth connectivity segment is expected to account for the larger share of the smart insulin pens market.
- This segment’s large market share can be attributed to the benefits offered by Bluetooth connectivity in smart insulin pens, such as the ability to connect and send information to mobile applications, the long range of connectivity, and the ability to provide insulin recommendations through the integration of CGM systems.
By Glucose Monitor Compatibility
- The Blood Glucose Monitors (BGMs) compatible pens segment is expected to account for the larger share of the smart insulin pens market.
- This segment's substantial share of the market is due to the benefits that BGMs provide over CGMs, such as lower cost, no need to connect equipment to the body, and no need to implant sensors into the user's skin.
By Purchase Channel
- The Retail Pharmacies to Dominate the Smart Insulin Pens Market
- The retail pharmacies segment is expected to account for the largest share of 49.2% of the smart insulin pens market.
- This segment’s large market share is attributed to the availability of retail pharmacies in nearby areas and the opportunity for customers to inspect the product before making a purchase.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 35% of the smart insulin pens market, followed by Europe and Asia-Pacific. North America’s significant market share can be attributed to several key factors, including the presence of major smart insulin pens companies such as Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), and Medtronic plc (Ireland), increasing healthcare expenditure, rising demand for self-administration of drugs, technological advancements in smart insulin pens, and rising number of diabetes cases in this region are some of the major factors driving the growth of the region.
Asia-Pacific
Fastest growthMoreover, the market in Asia-Pacific is expected to register the highest CAGR of 12.1% during the forecast period. The rise of this regional market can be ascribed to increased knowledge of smart insulin pens, diabetes awareness campaigns in countries such as China and India, and improved healthcare infrastructure.
Competitive landscape
- February 2024
Innovation Zed Ltd. (Ireland) received CE mark clearance in Europe for its InsulCheck Dose insulin pen, which provides real-time injection event data to a matching display device.
- December 2022
BIOCORP (France) received FDA 510(K) authorization to market Mallya, a smart medical device that connects insulin pens.
- November 2022
Eli Lilly and Company (U.S.) launched Tempo, a personalized diabetes management platform consisting of three components: Tempo Smart Button, TempoSmart app, and Tempo Pen prefilled insulin pen. This platform provides personalized guidance for adults with diabetes.
- Novo Nordisk A/S · Denmark
- Eli Lilly and Company (U.S.)
- Sanofi S.A. · France
- Medtronic plc · Ireland
- Emperra GmbH E-Health Technologies · Germany
- Jiangsu Delfu medical device Co., Ltd · China
- Tandem Diabetes Care, Inc. (U.S.)
- Ypsomed AG · Switzerland
- Bigfoot Biomedical, Inc. (U.S.)
Frequently asked questions
This study offers a detailed assessment of the smart insulin pens market sizes & forecasts based on product, connectivity, glucose monitor compatibility, and purchase channel. This report also involves the value analysis of various segments and subsegments of the smart insulin pens market at the regional and country levels.
Cite this report
Meticulous Research. (2024). Smart Insulin Pens Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041300). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/smart-insulin-pens-market-5983